President Donald Trump has directed his administration to speed up reviews of certain psychedelic drugs, including ibogaine.

The order instructs the FDA to expedite review of drugs such as ibogaine, a drug that veterans' groups have said can help treat post-traumatic stress disorder.

Order calls on federal government to relax restrictions on psychedelics, including ibogaine, for potential treatments.

By Kamal Choudhury April 20 (Reuters) - Shares of psychedelic drug developers rose on Monday after U.S. President Donald Trump signed an executive order directing health regulators to speed up reviews ...

Trump Targets Faster Access to Psychedelic Drugs for Mental Health. Here What That Means ...

President Donald Trump signed an executive order that directs the FDA to accelerate their review of "psychedelics already designated as breakthrough therapy drugs." ...

Executive order to speed access to psychedelic treatments likely to have limited legal impact despite high-profile push ...

The FDA announced efforts to expedite its research into perception-altering psychedelic medications.

The Food and Drug Administration said Friday it will offer ultra-fast review to three psychedelic drugs being developed to treat mental health conditions, including depression, the latest step by the ...

Like this article? Keep independent journalism alive. Support HuffPost. The Food and Drug Administration has announced efforts to expedite its research into perception-altering psychedelic medications ...